Given the well tolerated safety profile of activin inhibition in clinical phase II studies of cancer associated anemia and the lack of current therapeutic options in AP41, activin inhibition holds great promise as a therapeutic intervention in AP. The gene discussed is INHBE; the disease is anemia (phenotype).